Novo Nordisk Licenses Global Rights to Potential Haemostasis Therapy

Novo Nordisk has entered a global license agreement with French biotechnology company C2X Pharma and the French national institute for health and medical research (Inserm) for thrombin-activable factor X.
prdomain Business Register